These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 5005200)

  • 21. [Experimental evidence for Mycobacterium tuberculosis persistence in M. tuberculosis-infected H37RV mice in the treatment with 3 first-line drugs (rifampicin, isoniazid, pyrazinamide)].
    Smirnova TG; Chernousova LN; Andreevskaia SN; Nikolaeva GM
    Probl Tuberk Bolezn Legk; 2004; (3):32-7. PubMed ID: 15338898
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic potential of peptide deformylase inhibitors against experimental tuberculosis.
    Sharma A; Khuller GK; Kanwar AJ; Sharma S
    J Infect; 2010 Jun; 60(6):498-501. PubMed ID: 20346970
    [No Abstract]   [Full Text] [Related]  

  • 23. Growth inhibition of tubercle bacilli after pulsed exposures to combinations of antituberculous drugs.
    Beggs WH
    Res Commun Chem Pathol Pharmacol; 1975 Jul; 11(3):487-90. PubMed ID: 807961
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of radiation on microbiologic characteristics of M tuberculosis.
    Zack MB; Stottmeier K; Berg G; Kazemi H
    Chest; 1974 Sep; 66(3):240-3. PubMed ID: 4213816
    [No Abstract]   [Full Text] [Related]  

  • 25. [Changes in drug resistance of Mycobacteria in the simultaneous use of chemotherapy and intravenous infusions of dissolved ozone].
    Belianin II; Shmelev EI
    Probl Tuberk Bolezn Legk; 2004; (7):32-5. PubMed ID: 15379039
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lack of correlation between embB mutation and ethambutol MIC in Mycobacterium tuberculosis clinical isolates from China.
    Shi R; Zhang J; Otomo K; Zhang G; Sugawara I
    Antimicrob Agents Chemother; 2007 Dec; 51(12):4515-7. PubMed ID: 17846128
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increasing drug resistance of Mycobacterium tuberculosis isolates in Ontario, Canada, 1987-1998.
    Remis RS; Jamieson F; Chedore P; Haddad A; Vernich L
    Clin Infect Dis; 2000 Aug; 31(2):427-32. PubMed ID: 10987700
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rapid, automated, nonradiometric susceptibility testing of Mycobacterium tuberculosis complex to four first-line antituberculous drugs used in standard short-course chemotherapy.
    Johansen IS; Thomsen VØ; Marjamäki M; Sosnovskaja A; Lundgren B
    Diagn Microbiol Infect Dis; 2004 Oct; 50(2):103-7. PubMed ID: 15474318
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Biological properties of Mycobacterium tuberculosis in relation to sensitivity to antibacterial preparations].
    Gol'shevskaia VI; Grishina TA; Karpenko OL; Safonova SG; Grishina TD
    Probl Tuberk; 1995; (4):37-40. PubMed ID: 7567869
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Experimental in-vitro and in-vivo studies of the antibacterial effect of rifampicin and ethambutol].
    Kozulicyna TI; Korotajev GA
    G Ital Chemioter; 1972; 19(2):7-10. PubMed ID: 4199030
    [No Abstract]   [Full Text] [Related]  

  • 31. Drug resistance in tuberculosis.
    Ebrahim GJ
    J Trop Pediatr; 2007 Jun; 53(3):147-9. PubMed ID: 17526511
    [No Abstract]   [Full Text] [Related]  

  • 32. [Synergistic effects of davercin, rifampicin, ethambutol and isonicotinic acid hydrazide on selected standard strains of Mycobacterium in the in-vitro and in-vivo experiments].
    Janowiec M; Andrzejczyk Z; Szwedowicz I
    Pneumonol Pol; 1988 Jun; 56(6):278-82. PubMed ID: 3226945
    [No Abstract]   [Full Text] [Related]  

  • 33. [Studies on tubercle bacilli resistant to secondary drugs in the resected specimens and sputum of pulmonary tuberculosis patients].
    Kameda K; Kudo S; Iwai K; Ushikubo K
    Kekkaku; 1970 Sep; 45(9):283-7. PubMed ID: 4989932
    [No Abstract]   [Full Text] [Related]  

  • 34. [Resistance to antitubercular drugs in Chile].
    Valenzuela MT; Scheel G; Ponce J; Lepe R; Velasco M; Valenzuela P
    Rev Med Chil; 1984 Jan; 112(1):76-80. PubMed ID: 6429808
    [No Abstract]   [Full Text] [Related]  

  • 35. Sensititre® MYCOTB MIC plate for drug susceptibility testing of Mycobacterium tuberculosis complex isolates.
    Yu X; Ma YF; Jiang GL; Chen ST; Wang GR; Huang HR
    Int J Tuberc Lung Dis; 2016 Mar; 20(3):329-34. PubMed ID: 27046713
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mycobacterium resistance to antimycobacterial reagent.
    Aghandous R; Zouhdi M; Zizi M; Errami M; Idrissi L
    Therapie; 1999; 54(5):623-5. PubMed ID: 10667100
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Primary resistance of Mycobacterium tuberculosis in the province of Vizcaya].
    Echeverría MJ; Ayarza R; Jiménez MS; López de Goicoechea MJ; Berdonces P; Ibarretxebea AB
    Rev Esp Quimioter; 1999 Jun; 12(2):152-3. PubMed ID: 10562678
    [No Abstract]   [Full Text] [Related]  

  • 38. [Experimental study of 2d order tuberculostatic preparations in Mycobacterium bovis resistance to isoniazid or streptomycin (based on the data from a morphological study)].
    Golyshevskaia VI; El'shanskaia MP
    Farmakol Toksikol; 1975; 38(2):222-4. PubMed ID: 776650
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug resistance in tuberculosis in Delhi: a 2 year profile (2001--2002).
    Negi SS; Gupta S; Lal S
    J Commun Dis; 2003 Jun; 35(2):74-81. PubMed ID: 15562952
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Reasons for drug-resistant tuberculosis emergence].
    Tu DH
    Zhonghua Jie He He Hu Xi Za Zhi; 2007 Jun; 30(6):403-5. PubMed ID: 17673006
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.